| Theme | Genome medicine and novel therapeutic targets of kidney diseases | |
|---|---|---|
| Title | Mitochondria-targeting therapeutics for kidney diseases | |
| Publish Date | 2018/01 | |
| Author | Takehiro Suzuki | Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine / Division of Medical Science, Tohoku University Graduate School of Biomedical Engineering |
| Author | Takaaki Abe | Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine / Division of Medical Science, Tohoku University Graduate School of Biomedical Engineering / Department of Clinical Biology and Hormonal Regulation |
| [ Summary ] | Mitochondrial dysfunction causes various mitochondrial diseases by intracellular ATP depletion and increasing mitochondria-derived reactive oxygen species (mtROS). However the definitive and specific therapeutics for mitochondrial diseases have not yet been established. As renal reabsorption in tubular cells and the filtration barrier property in the glomerulus depend on ATP production by mitochondria, tubular dysfunction, nephrotic syndrome, and glomerular sclerosis are major complications of mitochondrial diseases. Mitochondrial dysfunctions are also involved in steroid resistant nephrotic syndrome, acute kidney injury, diabetic kidney disease and drug-induced nephropathy (cisplatin, contrast medium etc.). Mitochondria-targeting therapeutic strategies are a burgeoning field to treat mitochondrial dysfunction-related and more common kidney diseases. | |